Ipca Laboratories has informed that the US FDA conducted the inspection of the Company’s Formulations manufacturing Unit situated at Piparia (Silvassa) from 19th August, 2019 to 23rd August, 2019. At the conclusion of the inspection, the US FDA issued a Form 483 with 3 observations.
The above information is a part of company’s filings submitted to BSE.
